Quantcast

Latest hepatitis C Stories

2014-08-19 12:29:09

Dr. Joseph Boscarino's research into disease that claimed his brother a major breakthrough DANVILLE, Pa., Aug. 19, 2014 /PRNewswire-USNewswire/ -- A Geisinger researcher on a personal crusade against hepatitis C has been nominated for a Centers for Disease Control and Prevention (CDC) award recognizing his unprecedented approach to addressing a major public health concern. http://photos.prnewswire.com/prnvar/20140819/137456 Joseph Boscarino, Ph.D. MPH, senior scientist, Geisinger...

2014-08-19 12:28:29

Reimbursement and Out-of-Pocket Costs are the Leading Reasons for Treatment Discontinuation, According to Findings from Decision Resources Group BURLINGTON, Mass., Aug. 19, 2014 /PRNewswire/ -- Decision Resources Group finds that, for the treatment of hepatitis C virus (HCV) infections, 40 percent of surveyed HCV treating specialists expect to prescribe Gilead's investigational fixed-dose combination of sofosbuvir/ledipasvir in the next six months to their genotype 1 patients. Analysis of...

2014-08-05 11:43:07

University of Pittsburgh Schools of the Health Sciences Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the results of a predictive model developed at the University of Pittsburgh Graduate School of Public Health. The results of the analysis, funded by the National Institutes of Health (NIH) and performed with the University of Texas MD Anderson Cancer Center, are...

2014-08-04 23:00:29

Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the results of a predictive model developed at the University of Pittsburgh Graduate School of Public Health Pittsburgh, Pennsylvania (PRWEB) August 04, 2014 Newly implemented screening guidelines and improved, highly effective drug therapies could make hepatitis C a rare disease in the United States by 2036, according to the...

2014-07-29 23:15:48

Doctor Evidence, LLC has developed a comprehensive database of clinical evidence in Hepatitis C (HCV) to address the evolving needs of healthcare stakeholders. Santa Monica, CA (PRWEB) July 29, 2014 Doctor Evidence (“DRE”), the Santa Monica, California-based healthcare information leader has responded to marketplace clamor related to the transformative innovations in Hepatitis C virus (HCV) treatments with a comprehensive comparative effectiveness database that allows healthcare...

2014-07-29 23:13:49

San Antonio researcher leads national study that identified a combination of pills that cures 9 of 10 hepatitis C patients. San Antonio, TX (PRWEB) July 29, 2014 Researchers from The University of Texas Health Science Center at San Antonio, the Texas Liver Institute and other institutions have identified a combination of pills that cures 9 of 10 hepatitis C patients. The combination of the drugs sofosbuvir and simeprevir, with or without ribavirin, cured 93 percent of patients in 12...

2014-07-29 23:03:41

New Treatments Can Significantly Transform the Face of Hep C LA JOLLA, Calif. (PRWEB) July 29, 2014 CHI-California Healthcare Institute today unveiled a report that provides a comprehensive overview of the hepatitis C (hep C) epidemic in the U.S., the rise of treatments and the potential of these treatments to reduce human suffering. The report examines key data to provide a broader understanding of the impact of hep C, while highlighting the significance of breakthroughs that have...

2014-07-28 13:20:36

The Lancet Infected patients and could improve treatment uptake Two new pill-only antiviral drug regimens could provide shorter, more effective treatment options with fewer side effects for the majority of patients infected with hepatitis C, even those most difficult to treat, according to the results of two studies published in The Lancet. Both studies focused on hepatitis C genotype 1, which is the most common genotype in the USA, Europe, North Asia, Australia, and South America,...

2014-07-28 08:28:50

New study identifies potential alternatives to Gilead's Sovaldi PHILADELPHIA, July 28, 2014 /PRNewswire/ -- The Intellectual Property and Science business of Thomson Reuters, the world's leading source of intelligent information for businesses and professionals, today released a new study in recognition of World Hepatitis Day on Life Sciences Connect, a blog exploring the latest news and trends in Life Sciences and updates on the drug pipeline identifying multiple treatments in...

2014-07-25 09:45:29

University of Cincinnati Academic Health Center Treatment of HIV patients co-infected with the hepatitis C virus (HCV) with an anti-retroviral drug therapy not only tackles HIV, but also reduces HCV replication, according to a new study lead by a University of Cincinnati researcher. The results were published Wednesday, July 23, 2014, in Science Translational Medicine. Previously, physicians treating co-infected patients worried that HIV antiretroviral therapy might injure the liver...


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related